Related references
Note: Only part of the references are listed.Succinate dehydrogenase (SDH)-deficient neoplasia
Anthony J. Gill
HISTOPATHOLOGY (2018)
Emerging and evolving concepts in gene essentiality
Giulia Rancati et al.
NATURE REVIEWS GENETICS (2018)
Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer
Hui Liu et al.
CANCER DISCOVERY (2018)
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Andrew J. Aguirre et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
Remco J. Molenaar et al.
CLINICAL CANCER RESEARCH (2018)
Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells
Juan I. Garaycoechea et al.
NATURE (2018)
CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine
Martin Kampmann
ACS CHEMICAL BIOLOGY (2018)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma
J. M. Thompson et al.
ONCOGENE (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
The genetic landscape of endometrial clear cell carcinomas
Deborah F. DeLair et al.
JOURNAL OF PATHOLOGY (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
Amy Drean et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Prasenjit Dey et al.
NATURE (2017)
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Di Zhao et al.
NATURE (2017)
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Benjamin G. Bitler et al.
NATURE CELL BIOLOGY (2017)
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells
Robin M. Meyers et al.
NATURE GENETICS (2017)
Marked for death: targeting epigenetic changes in cancer
Sophia Xiao Pfister et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
Thomas Januario et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
Abhishek A. Chakraborty et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Georg Karpel-Massler et al.
NATURE COMMUNICATIONS (2017)
A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events
Colm J. Ryan et al.
CELL SYSTEMS (2017)
Strategies to Inhibit Myc and Their Clinical Applicability
Jonathan R. Whitfield et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
Eliana M. C. Tacconi et al.
EMBO MOLECULAR MEDICINE (2017)
Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy
Sarah R. Hengel et al.
CELL CHEMICAL BIOLOGY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Defining a Cancer Dependency Map
Aviad Tsherniak et al.
CELL (2017)
Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
Tim Wang et al.
CELL (2017)
Targeting MYC in cancer therapy: RNA processing offers new opportunities
Cheryl M. Koh et al.
BIOESSAYS (2016)
Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens
Atray Dixit et al.
CELL (2016)
PARP inhibitor combination therapy
Amy Drean et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Comprehensive mutation profiling of mucinous gastric carcinoma
Hirofumi Rokutan et al.
JOURNAL OF PATHOLOGY (2016)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann et al.
LANCET ONCOLOGY (2016)
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Rowan E. Miller et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
Roman Camarda et al.
NATURE MEDICINE (2016)
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression
Dai Horiuchi et al.
NATURE MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Konstantinos J. Mavrakis et al.
SCIENCE (2016)
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Gregory V. Kryukov et al.
SCIENCE (2016)
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
James Campbell et al.
CELL REPORTS (2016)
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
Katya Marjon et al.
CELL REPORTS (2016)
Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage
Cosetta Bertoli et al.
CELL REPORTS (2016)
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Sophia X. Pfister et al.
CANCER CELL (2015)
A Synergistic Interaction between Chk1-and MK2 Inhibitors in KRAS-Mutant Cancer
Felix Dietlein et al.
CELL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Julian Downward
CLINICAL CANCER RESEARCH (2015)
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
Marwan Kwok et al.
LANCET (2015)
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Raphael Ceccaldi et al.
NATURE (2015)
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Pedro A. Mateos-Gomez et al.
NATURE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis
Simone Cardaci et al.
NATURE CELL BIOLOGY (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Naoko Takebe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation
Evrim Gurpinar et al.
TRENDS IN CELL BIOLOGY (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics
Cigall Kadoch et al.
SCIENCE ADVANCES (2015)
Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response
Elda Grabocka et al.
CLINICAL CANCER RESEARCH (2015)
Targeting RNA polymerase I to treat MYC-driven cancer
G. Poortinga et al.
ONCOGENE (2015)
Collateral Lethality: A New Therapeutic Strategy in Oncology
Florian L. Muller et al.
TRENDS IN CANCER (2015)
ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
Kareem N. Mohni et al.
CANCER RESEARCH (2014)
BRG1/SMARCA4 Inactivation Promotes Non-Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization
Tess Orvis et al.
CANCER RESEARCH (2014)
Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
Boris G. Wilson et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
Gregory R. Hoffman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition
Eleftherios P. Samartzis et al.
ONCOTARGET (2014)
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Kimberly Cramer-Morales et al.
BLOOD (2013)
A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
Takahiro Oike et al.
CANCER RESEARCH (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Christopher J. Lord et al.
NATURE MEDICINE (2013)
Survival of the Replication Checkpoint Deficient Cells Requires MUS81-RAD52 Function
Ivana Murfuni et al.
PLOS GENETICS (2013)
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Madhu S. Kumar et al.
CELL (2012)
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
Michael Steckel et al.
CELL RESEARCH (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Passenger deletions generate therapeutic vulnerabilities in cancer
Florian L. Muller et al.
NATURE (2012)
Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation
David Nittner et al.
NATURE CELL BIOLOGY (2012)
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators
Akihiro Fujimoto et al.
NATURE GENETICS (2012)
Functional genomics identifies therapeutic targets for MYC-driven cancer
Masafumi Toyoshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Jessica D. Kessler et al.
SCIENCE (2012)
The p53 network: cellular and systemic DNA damage responses in aging and cancer
H. Christian Reinhardt et al.
TRENDS IN GENETICS (2012)
Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Richard Marcotte et al.
CANCER DISCOVERY (2012)
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
Thomas De Raedt et al.
CANCER CELL (2011)
STK33 Kinase Is Not Essential in KRAS-Dependent Cells-Letter
Stefan Frohling et al.
CANCER RESEARCH (2011)
Genetic Interactions in Cancer Progression and Treatment
Alan Ashworth et al.
CELL (2011)
Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin
Sophie Chantalat et al.
GENOME RESEARCH (2011)
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
Christian Frezza et al.
NATURE (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Rad52 inactivation is synthetically lethal with BRCA2 deficiency
Zhihui Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
SWI/SNF nucleosome remodellers and cancer
Boris G. Wilson et al.
NATURE REVIEWS CANCER (2011)
Specific Killing of Rb Mutant Cancer Cells by Inactivating TSC2
Binghui Li et al.
CANCER CELL (2010)
Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
Oren Gilad et al.
CANCER RESEARCH (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Stefano Campaner et al.
NATURE CELL BIOLOGY (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling Complex
Xi Wang et al.
CANCER RESEARCH (2009)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Claudia Scholl et al.
CELL (2009)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing
Kirk J. McManus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy
Sandra Turcotte et al.
CANCER CELL (2008)
Evolutionary plasticity of genetic interaction networks
Julia Tischler et al.
NATURE GENETICS (2008)
Characterization of mismatch and high-signal intensity probes associated with Affymetrix genechips
Yonghong Wang et al.
BIOINFORMATICS (2007)
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Andrei Goga et al.
NATURE MEDICINE (2007)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation
MT Pickering et al.
ONCOGENE (2006)
The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes
H Xiao et al.
ONCOGENE (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Global mapping of the yeast genetic interaction network
AHY Tong et al.
SCIENCE (2004)
Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours
J Mora et al.
BRITISH JOURNAL OF CANCER (2004)
Systematic genetic analysis with ordered arrays of yeast deletion mutants
AHY Tong et al.
SCIENCE (2001)
Share Paper
